魏正宗 Cheng-Chung Wei

臨床科別：過敏免疫風濕科

聯絡分機：#34726

電子郵件：wei3228@gmail.com

專長

僵直性脊椎　自體免疫疾病　風濕關節炎　紅斑狼瘡

免疫　臨床試驗　痛風　整合醫學　過敏

學歷

中山醫學大學醫學研究所博士
中國醫藥大學中西醫結合研究所碩士班
國立陽明大學醫學系
英國皇家國立風濕病醫院(RNHRD)研究進修法國巴黎第五大學Colchin醫院進修
美國加州大學UCLA免疫風濕實驗室研究員

經歷

台中榮總家庭醫學科醫師
高雄榮總過敏免疫風濕科總醫師
過敏免疫科、風濕科、內科、家醫科、中西結合專科醫師嘉義榮民醫院家庭醫學科主任
中華民國僵直性脊椎炎關懷協會第二屆理事長
中山醫學大學附設醫院人體試驗委員會主任委員
行政院衛生署人體試驗/研究倫理委員會訪查委員

臨床試驗(執行中)

1. 為期 52 週的隨機、雙盲、安慰劑對照研究，目的在於評估活性自體抗體呈陽性的全身性紅斑狼瘡成年患者使用 Belimumab 後應特別注意的不良事件

2. 一項以患有類風濕性關節炎之患者為對象，評估 baricitinib 長期安全性暨療效之第三期多中心試驗
3. 使用TOFACITINIB（CP-690,550）治療乾癬性關節炎的長期、開放、延伸性試驗
4. 評估兩種劑量的Tofacitinib與一種腫瘤壞死因子抑制劑 (TNFi) 用於類風濕性關節炎受試者的第 3B/4 期隨機分配安全性指標試驗
5. 以大數據研究免疫風濕疾病及藥物之長期效益以及風險
6. SpA登錄計畫及免疫基因體研究
7. 微生物菌相與唾液蛋白質組學在臨床診斷的應用與探討
8. 以人工智慧深度學習建立免疫風濕疾病影像自動判讀系統
9. 一項隨機分配、雙盲、安慰劑對照驗證試驗，在對MTX反應不足或無法耐受的類風濕性關節炎(RA)患者中，評估ASP015K的安全性與療效
10. 篩選帶有HLA同合子之細胞捐贈者
11. 風濕免疫疾病影響子代健康- 一項全國大數據的觀察型研究
12. 中軸型脊椎關節炎前瞻世代研究分類
13. 台灣中重度風濕性關節疾病患者，生物製劑(TNF inhibitor)中斷使用之流病分析，2010-2017年全國健保資料庫研究
14. 一項第3期、多中心、隨機分配、雙盲、安慰劑與活性藥物對照試驗，針對中度至重度斑塊型乾癬的受試者評估以Guselkumab治療的療效與安全性
15. 一項多中心、隨機分配、雙盲、安慰劑對照的24週試驗接續長期評估使用Ixekizumab （LY2439821）於經歷生物疾病修飾抗風濕病藥物（bDMARD）的活性乾癬性關節炎（PsA）病患之療效與安全性
16. 針對充分達到24週反應的無X光異常之早期軸心型脊椎關節炎受試者，評估停止接受與再度接受ETANERCEPT治療的一項多中心、開放性試驗
17. 一項第 3 期、多中心、隨機分配、安慰劑對照的雙盲試驗，在罹患活動性軸心型脊椎關節炎 (AxSpA) 且沒有僵直性脊椎炎 (AS) 之 X 光證據及客觀發炎徵象的受試者中，評估 Certolizumab Pegol 的療效及安全性
18. 一項第三期、隨機分配、雙盲之臨床試驗，比較ABT-494、Adalimumab與安慰劑於接受穩定劑量之Methotrexate(MTX)治療未獲良好控制之中重度活動性類風濕性關節炎患者之安全性與療效

19. 一項隨機分配、雙盲、平行分組、多中心試驗，在抗腫瘤壞死因子（TNF）療法療效反應不足且正在接受背景methotrexate (MTX) 療法的中至重度類風濕性關節炎 (RA) 病患中，比較JHL1101與在歐盟上市的MabThera®的藥物動力學、藥效學、免疫原性、安全性及療效
20. 一項隨機分配、雙盲、安慰劑和活性藥物對照、多中心、第三期試驗，在罹患中至重度活動性類風濕性關節炎，且對Methotrexate 療效反應不足的受試者中，評估 Filgotinib 與 Methotrexate 併用 52 週的療效及安全性
21. 以軸心型脊椎關節炎病患評估Ixekizumab (LY2439821) 療效維持情況之一項104週多中心、長期延伸試驗 (包括一個雙盲、安慰劑對照40週隨機分配退出-再度治療期)
22. 一項第三期多中心、隨機分配、雙盲、安慰劑對照及開放性延伸試驗，評估KHK4827 對軸心型脊椎關節炎受試者之療效與安全性
23. 一項第三期、多中心、隨機分配、雙盲、安慰劑對照試驗，於患有活動性乾癬性關節炎的受試者，包括曾接受抗腫瘤壞死因子(TNFα)生物製劑治療者，評估皮下給予Guselkumab之療效和安全性
24. 針對曾對至少一種非生物性疾病修飾型抗風濕藥物(DMARD)反應不佳的活動性乾癬性關節炎受試者中，對Upadacitinib(ABT-494)與安慰劑以及Adalimumab進行比較的一項第三期、隨機分配、雙盲試驗 - SELECT –PsA 1
25. 一項多中心、雙盲、長期延伸試驗，在罹患類風濕性關節炎的受試者中，評估 Filgotinib 的安全性和療效
26. 一項針對在台灣接受Adalimumab療法的僵直性脊椎炎病患探討臨床反應的真實世界、前瞻性、觀察性試驗
27. 一項隨機分配、雙盲、安慰劑對照的多機構合作臨床試驗，於誘導劑量期之後進行隨機停藥維持劑量期，以評估Mirikizumab在中度至重度斑塊型乾癬病患中的療效與安全性
28. 隨機、部分盲性、活性藥物對照的多中心試驗，評估 secukinumab 用於活動性僵直性脊椎炎患者，治療 104 週相較於 GP2017 (adalimumab 生技仿製藥) 的放射影像惡化減少之療效，以及持續 2 年的長期安全性、耐受性及療效
29. 一項隨機分配、雙盲、安慰劑對照的第二期試驗，在患有全身性紅斑性狼瘡的受試者中，評估 BMS-986165 的療效及安全性

30. 一項多中心、隨機分配、雙盲、安慰劑對照、平行分組，使用 Ustekinumab 於活動性全身性紅斑性狼瘡受試者的試驗
31. 脊椎關節炎的週邊關節侵犯之評估研究
32. 一項多中心、長期延伸試驗，評估Mirikizumab於中度至重度斑塊型乾癬病患的長期安全性與維持治療效果
33. 針對曾對於至少一種疾病調節抗風濕藥物(DMARD)治療反應不佳或無法耐受的活動性乾癬性關節炎(PsA)受試者使用Risankizumab與安慰劑進行比較之第3期、隨機分配、雙盲性試驗
34. 一項多中心試驗，針對患有全身性紅斑性狼瘡的受試者，描述 BMS-986165 的長期安全性及療效特性
35. 一項第 2B 期、雙盲、隨機、安慰劑對照、多中心、劑量範圍試驗，旨在評估 PF-06700841 在 活動性全身性紅斑性狼瘡 (SLE) 患者中的療效和安全性

臨床試驗(已結案)

1. 僵直性脊椎炎之中藥方劑療效評估
2. 開放性、多中心臨床試驗以評估台灣慢性乾癬症病患接受每週 肌肉注射AMEVIVE一個療程後之療效及安全性
3. 中藥方劑治療僵直性脊椎炎之先導性臨床試驗
4. 以基因微陣列法研究「僵直性脊椎炎」之基因表達
5. 喜樂美食品治療高尿酸血症病人之先導性研究
6. 以『自律神經分析儀』探討僵直性脊椎炎與其他免疫疾病病人自律神經功能之研究
7. Moducare®治療過敏性鼻炎之隨機雙盲安慰劑對照式臨床試驗
8. 沙利竇邁治療結節性癢疹之療效評估計畫
9. 奈米珍珠鈣抗氧化延緩衰老及增進鈣生物利用率
10. AGTC-179治療風濕病之隨機雙盲安慰劑控制式之臨床試驗
11. 非侵入性研究僵直性脊椎炎的基因多型性相關研究
12. 中藥方劑治療高尿酸血症之先導性試驗
13. 破骨細胞與內質網壓力在僵直性脊椎炎致病機制中所扮演的角色
14. MORA生物能共振檢測儀用於過敏病患之臨床試驗
15. 以etanercept治療僵直性脊椎炎的多中心、開放性研究
16. 以高頻熱凝療法阻斷腰椎脊神經內側枝治療腰椎小面關節症候群
17. 國際性、多中心研究利用僵直性脊椎炎療效評估標準量表作為脊椎關節炎病患分類標準

18. 抗腫瘤壞死因子(enbrel)對僵直性脊椎炎血清中TLR, BMP, TARIL, MMP及多種cytokines(TNF, IL18, IL6, IL8, IL10, IL1)等之影響
19. Pioglitazone hydrochloride 30mg 錠劑生體相等性試驗
20. 比較Etoricoxib 與 Aceclofenac 對類風濕性關節炎患者的療效
21. 中藥方劑治療高尿酸血症之先導性試驗
22. 一個開放性的試驗以評估MabThera® (rituximab)用於治療對一種或多種抗腫瘤壞死因子藥物反應不佳或耐受性不佳的類風濕性關節炎發作病患
23. 痛風散治療高尿酸血症之先導性試驗
24. 免疫調節草本複方食品莊松榮精氣神茶飲之隨機雙盲安慰劑控制式臨床試驗
25. 一個自第II至III階段、多中心、隨機、雙盲、以安慰劑對照之臨床研究。Abatacept相對於安慰劑對正在接受Mycophenolate Mofetil 及Glucocorticosteroids治療因全身紅斑性狼瘡引起活動性增生性腎絲球體腎炎之受試者其療效和安全性的評估
26. 一項第三期、多中心、隨機分配、雙盲、安慰劑對照、52週的研究，評估全人類BLyS單株抗體 Belimumab (HGS1006, LymphoStat-B™) 對於全身性紅斑狼瘡(SLE) 受試者的療效和安全性
27. Health Baby裝置之心率變異分析與體溫功能評估研究
28. Tramadol/Acetaminophen (Ultracet®)藥劑附加治療於僵直性脊椎炎病患
29. 比較Etanercept 與Adalimumab治療於僵直性脊椎炎病患
30. 第三階段、多中心、隨機分派、雙盲、雙啞 之對照研究，比較Abatacept以皮下注射與靜脈注射用於正在使用Methotrexate治療類風濕性關 節炎但對Methotrexate反應不足的患者，其療效與安全性之評估
31. 丹參附加西藥於台灣原發性高血壓病患之有效性與耐受性—十二週之隨機、雙盲、安慰劑控制式臨床試驗
32. 評估Thalidomide治療合併有關節炎或無關節炎之斑塊尋常性乾癬病患之有效性與安全性 - 二十四週之隨機、雙盲、安慰劑控制式臨床試驗
33. 一項多中心，將全人類BLyS單株抗體 Belimumab (HGS1006,LymphoStat-B™)用於完成第三期 HGS1006-C1056 或 HGS1006-C1057 試驗計畫之全身性紅斑狼瘡 (SLE) 受試者的延續試驗
34. 評估樟芝輔助改善類風濕性關節炎之有效性與安全性 - 一項為期十二週、隨機、雙盲、安慰劑、控制式臨床試驗

35. 計畫性細胞死亡-1及其配位基與第四類細胞毒殺性T淋巴抗原基因多形性與台灣僵直性脊椎炎之相關性
36. 評估保健食品Domilex輔助改善類風濕性關節炎之隨機雙盲安慰劑控制式臨床試驗
37. 併用疾病修飾性抗風濕病藥物(DMARD)治療活動期類風濕性關節炎的病人，接受LY2439821(抗IL-17抗體)多劑皮下注射的第2期劑量變動試驗
38. 一項隨機、開放、對照式臨床試驗評估抗腫瘤壞死因子生物製劑治療僵直性脊椎炎患者合併使用非類固醇消炎止痛藥之安全性與有效性
39. 紅麴加上益生菌對降血脂作用之評估-生化分析及機轉研究
40. 中藥複方OA 1改善骨關節炎症狀之人體試驗 - 一項為期十二週之隨機雙盲安慰劑對照式臨床試驗
41. 建立以醫院為基礎的僵直性脊椎炎病患世代，並且探討骨骼重塑與自體免疫耐受性的可能效應
42. 雪樟芝輔助改善C型肝炎之十二週隨機雙盲安慰劑控制式臨床試驗
43. 一項多中心、12週、雙盲、安慰劑對照、隨機分配的試驗，以恩博併用非類固醇消炎止痛藥治療無影像學變化之中軸脊椎關節炎成年患者，並進行為期92週開放性延伸研究
44. TNF-α、TNF-α接受器與microRNA-146a基因多形性與僵直性脊椎炎發生之相關
45. 一項第III 期、2 階段、隨機分配、雙盲、安慰劑對照、多中心臨床試驗，評估2種MK-0663/Etoricoxib 劑量用於類風濕性關節炎病患時的相對療效和耐受性
46. 一項第III 期、2 階段、隨機分配、雙盲、安慰劑對照、多中心臨床試驗，評估2種MK-0663/Etoricoxib 劑量用於類風濕性關節炎病患時的相對療效和耐受性
47. 在僵直性脊椎炎病患中測試MK-0663/Etoricoxib2種劑量之相對療效和耐受性的一項第Ⅲ期、2階段、隨機分配、雙盲、活性對照、多中心臨床試驗
48. 一個採隨機、安慰劑控制評估Tocilizumab合併使用Methortrexate在治療中度至重度的類風濕性關節炎患者之臨床試驗
49. 一項針對活動性乾癬性關節炎受試者評估使用兩種Apremilast（CC-10004）劑量的第3期、多中心、隨機分配、雙盲、安慰劑對照、平行分組之療效與安全性試驗

50. 一項第三期、多中心、隨機分配、雙盲、安慰劑對照試驗，評估全身性紅斑性狼瘡(SLE)病患使用皮下注射LY2127399的療效與安全性
51. 一項評估全身性紅斑性狼瘡受試者使用A-623的療效、安全性和耐受性之隨機雙盲第2b期試驗
52. 表面擴散係數分析在修格連氏症候群腮腺之研究
53. 隨機分組、雙盲、以安慰劑對照的劑量範圍決定試驗：針對先前以TNF 阻斷劑治療無效的活躍性類風濕性關節炎病患，評估以皮下注射方式使用CDP6038治療12週的療效與安全性。第二期
54. 隨機、雙盲、安慰劑對照的多機構合作試驗，研究以 secukinumab 治療 16 週的療效，並持續 2 年評估活動性僵直性脊椎炎患者的長期安全性、耐受性與療效
55. 一項第三期、多中心、隨機分配、雙盲、安慰劑對照的平行試驗，評估以兩種口服CP-690,550劑量治療中度至重度慢性斑塊型牛皮癬患者的療效及安全性
56. 紅景天輔助改善慢性阻塞性肺病之隨機雙盲安慰劑控制式臨床試驗及機轉
57. 一項第三期、多中心、開放性試驗，評估以兩種口服CP-690,550劑量治療中度至重度慢性斑塊型牛皮癬患者的長期安全性及耐受性
58. 這是一項第2期、多中心、開放標示、追蹤試驗，用以評估完成RA0083試驗活動性類風濕性關節炎的亞洲受試者，以皮下注射接受CDP6038的長期安全性與療效
59. 一項開放性、長期的安全性延伸試驗，針對已完成AN-SLE3321 (PEARL-SC)試驗計劃之全身性紅斑性狼瘡受試者
60. (OSKIRA-Asia-1X)：在亞洲進行的一項長期試驗，評估Fostamatinib用於治療類風濕性關節炎的安全性
61. 一項針對全身性紅斑性狼瘡（Systemic Lupus Erythematosus）受試者評估MEDI-546之療效與安全性的第二期、隨機分組試驗
62. 一項第3b期、多中心、開放試驗，評估紅斑性狼瘡 (SLE) 病患接受LY2127399皮下注射劑之長期療效與安全性 (ILLUMINATE - X)
63. 一項前瞻性、隨機、雙盲、安慰劑對照、平行性、多中心、第三期試驗，評估ENIA11併用Methotrexate與單用Methotrexate治療類風濕性關節炎病患的療效性與安全性
64. 一項前瞻性、隨機、雙盲、安慰劑對照、平行性、多中心、第三期試驗，評估ENIA11併用Methotrexate與單用Methotrexate治療類風濕性關節炎病患的療效性與安全性

65. 一項對接受DMARD藥物治療後仍有活動性類風濕性關節炎的受試者以皮下注射給予CNTO 136 (sirukumab，一種人類抗介白素6 [IL-6]單株抗體)的多中心、隨機分配、雙盲、安慰劑對照、平行分組之試驗
66. 一項對接受抗腫瘤壞死因子α (Anti-TNFα)療法後仍有活動性類風濕性關節炎的受試者以皮下注射給予CNTO 136 (sirukumab，一種人類抗介白素6 [IL-6]單株抗體)的多中心、隨機分配、雙盲、安慰劑對照、平行分組之試驗
67. 一項以患有中度到重度活動性類風濕性關節炎，且經methotrexate 治療後反應不佳之患者為對象，評估接受baricitinib 療法所得療效與安全性之隨機、雙盲、安慰劑暨活性對照第三期試驗
68. 此多國、橫斷式研究乃為了解全身慢性免疫疾病病患，對於服藥用治療順從性的一般與特殊認知
69. 評估AC-201用於接受降尿酸藥治療的痛風患者之隨機、雙盲、安慰劑對照之二期臨床試驗
70. 隨機分配、雙盲、安慰劑對照之第三期臨床試驗，評估Baricitinib (LY3009104) 用於使用傳統疾病修飾抗類風濕藥物反應不佳之中度至重度活動性類風濕性關節炎患者之療效與安全性
71. 一項評估非生物性 DMARD 療法中加入 sarilumab （用於接受TNF-α 拮抗劑但無獲得充分緩解或無法耐受之類風濕性關節炎患者）的療效與安全性之隨機分配、雙盲、平行組、安慰劑對照研究
72. 藥物基因體學分析強直性脊柱炎患者TNF-α受體阻滯劑治療的反應偵測
73. 脊椎關節炎之合併症流行病學研究
74. 102年度「教學醫院成立中藥臨床試驗中心」
75. 一項評估Blisibimod用於全身性紅斑狼瘡受試者之療效與安全性的隨機分配、雙盲、安慰劑對照、第3期試驗
76. 評估 Tofacitinib 治療患有活動性僵直性脊椎炎 (AS) 受試者的療效及安全性，在一項第二期、隨機分配、雙盲、安慰劑對照、劑量範圍的研究
77. 骨質疏鬆症的藥物使用模式、治療滿意度和控制不力研究(MUSIC-OS)：亞太地區停經後婦女在骨質疏鬆症治療方面的臨床實務研究
78. 微型核醣核酸-125b及其標的基因TNF-α與僵直性脊椎炎之相關

79. 一項第 3 期、隨機分組、雙盲、安慰劑控制的試驗，評估 2 種劑量的 Tofacitinib (CP-690,550) 或 Adalimumab 對於活動性乾癬性關節炎病患的療效及安全性
80. 生物製劑減量及暫緩續用對於類風濕性關節炎患者的臨床表現及醫療資源使用情況影響的回溯性病歷研究
81. 評估 secukinumab 治療活動性僵直性脊椎炎患者之臨床效益持續性、安全性、及耐受性之延伸試驗
82. 評估新興市場的風濕門診中，早期無X光中軸型脊椎關節炎(non-radiographic Axial SpA)在慢性發炎性背痛病患的盛行率之橫斷式前瞻性非介入性之流行病學研究
83. 一項針對已於 CNTO136ARA3002 (SIRROUND-D) 與 CNTO136ARA3003 (SIRROUND-T) 試驗中完成治療的類風濕性關節炎受試者研究CNTO136 (sirukumab)長期安全性與療效的多中心、平行分組試驗
84. 在僵直性脊椎炎中，循環微型核糖核酸 (miR-27, miR-29, miR-125b, miR-146a, miR-155) 與其標的基因、發炎體基因多形性、骨重塑與發炎標記、以及臨床表徵之相關
85. 一項以患有僵直性脊椎炎的受試者為對象，採用三種劑量、以皮下方式給予藥物BI 655066，用以證明概念及探索劑量，且為期 48 週的第二期、隨機分配、雙盲、安慰劑對照試驗
86. 一項第 3 期、隨機分配、雙盲、安慰劑對照的試驗，評估 2 種劑量的 TOFACITINIB (CP-690,550)在活動性乾癬性關節炎及對至少一種 TNF 抑制劑反應不足之受試者的療效與安全性
87. 一項第 3b /4 期隨機分配、雙盲的試驗，在中度至嚴重活動性類風濕性關節炎受試者中， 比較5 毫克劑量的 tofacitinib 併用及不併用 methotrexate，與 adalimumab 併用 methotrexate 的研究
88. 一項第三期隨機分配、雙盲試驗，針對曾對於METHOTREXATE反應不佳的中度至重度活動性類風濕性關節炎受試者，評估PF-06410293與ADALIMUMAB併用METHOTREXATE的療效和安全性
89. 以健保資料庫分析台灣常見風濕病之全國流行病學調查及共病研究
90. 教學醫院推動中藥臨床試驗療效評估
91. 口腔微生物菌相及唾液蛋白質組學在口腔乾燥診斷上的應用
92. 低劑量電腦斷層在僵直性脊椎炎之應用

93. 一項第3期、多中心、隨機分配、雙盲試驗，針對中度至重度斑塊型乾癬且對Ustekinumab反應不佳的受試者評估以Guselkumab治療的療效與安全性
94. 一項使用Ustekinumab治療活動性全身性紅斑性狼瘡病患的多中心、隨機分配、雙盲、安慰劑對照、概念驗證試驗
95. 一項針對未曾使用抗腫瘤壞死因子(TNFα)藥物之活動性放射影像軸心型脊椎關節炎受試者，評估Ustekinumab療效和安全性的第三期、多中心、隨機分配、雙盲、安慰劑對照試驗
96. 一項針對具有抗腫瘤壞死因子(TNFα)藥物頑抗性之活動性放射影像軸心型脊椎關節炎受試者，評估Ustekinumab療效和安全性的第三期、多中心、隨機分配、雙盲、安慰劑對照試驗
97. 一項針對活動性無放射影像異常之早期軸心型脊椎關節炎受試者評估Ustekinumab療效和安全性的第三期、多中心、隨機分配、雙盲、安慰劑對照試驗
98. ASAS 健康量表之國際信效度研究計畫
99. 一項隨機分配、雙盲、安慰劑對照確認試驗，評估 ASP015K 用於疾病修飾型抗風濕藥物 (DMARD) 治療反應不佳的類風濕性關節炎 (RA) 患者之安全性與療效
100. 多中心、開放性(A部分)後進行隨機分配、雙盲、平行分組、安慰劑對照試驗(B部分)，針對患有活性軸心型脊椎關節炎(axSpA)的受試者，接受Certolizumab pegol 200 mg每2週一次(Q2W)或200 mg每4週一次(Q4W)，相較於安慰劑治療，評估維持緩解的效果
101. 一個第IIb期、隨機、雙盲、安慰劑對照研究，評估干擾素基因標記的中和作用，以及IFNα-Kinoid 對全身性紅斑狼瘡成人患者的臨床療效標記
102. Ixekizumab (LY2439821) 使用於未曾接受bDMARD之放射線影像異常軸心型脊椎關節炎病患的一項多中心、隨機分配、雙盲、活性藥物與安慰劑對照16週試驗與安全性及療效之長期評估追蹤
103. 一項隨機、雙盲、雙虛擬、多中心、活性對照試驗，在患有潰瘍性結腸炎的受試者中，評估靜脈注射型Vedolizumab相較於皮下注射型Adalimumab的療效及安全性
104. 針對 Baricitinib 在全身紅斑性狼瘡 (Systemic Lupus Erythematosus，SLE) 病患的隨機分配、雙盲、安慰劑對照、平行分組、第2期試驗
105. 一項針對健康受試者的第1期、隨機分配、雙盲、安慰劑對照、單劑遞增劑量試驗，以及針對輕度至中度全身性紅斑性狼瘡受試者的JNJ-55920839多重劑量試驗 - B部分

106.第2期、隨機分配、多中心、雙盲、劑量範圍、安慰劑對照的調整設計試驗，針對罹患中度至重度類風濕性關節炎且對Methotrexate併用或不併用腫瘤壞死因子(TNF)抑制劑反應不足的受試者，評估BMS-986142的療效與安全性/藥物動力學
107.一項在活動性乾癬性關節炎患者中探討BI 655066/ABBV-066/risankizumab的隨機、雙盲、安慰劑對照、概念驗證、劑量範圍試驗
108.探討藉由ASAS提出11項心理測量評估中軸型脊椎關節炎病發之特徵研究
109.一項第3期、隨機分配、雙盲、活性藥物對照、多中心試驗，於髖關節或膝關節骨關節炎的受試者皮下注射tanezumab長期安全性與療效研究
110.ASP015K 延伸試驗–開放標記延伸試驗，對象為完成 ASP015K 第 IIb 期或第 III 期試驗的類風濕性關節炎患者
111.針對接受全膝關節、全髖關節或全肩關節置換術的Tanezumab試驗受試者所進行的一項第3期、多中心、長期觀察性試驗
112.一項隨機分配、雙盲、安慰劑和活性藥物對照、多中心、第三期試驗，在罹患中至重度活動性類風濕性關節炎，且未曾接受 Methotrexate (MTX) 療法的受試者中，評估單獨使用 Filgotinib 與併用 MTX 52 週的療效及安全性
113.針對已於試驗1311.5中完成第24週回診之乾癬性關節炎受試者，研究Risankizumab安全性的一項第2期、單組、開放性延伸試驗
114.以單一劑量TLC599注射退化性膝關節炎病患之一項第IIa期、隨機分配、雙盲、安慰劑對照、劑量探索臨床試驗

個人近期著作

1. Julia Liu, JC Wei. HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis. JCI accepted 2019
2. Liu YT, Tsou HK, Chiou JY, Wang YH, Chou MC, Wei JC*. Association of human papillomavirus infection with risk for rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215931

3. Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019 Jul 26. pii: annrheumdis-2019-215163.
4. Chang CM, Hsu YW, Wong HS, Wei JC, Liu X, Liao HT, Chang WC. Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies. Dis Markers. 2019 Jul 7;2019:2364943
5. Yen FS, Wang HC, Pan CW, Wei JC, Hsu CC, Hwu CM. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.J Clin Endocrinol Metab. 2019 Sep 23
6. Yen FS, Wang HC, Pan CW, Wei JC, Hsu CC, Hwu CM. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.J Clin Endocrinol Metab. 2019 Sep 23
7. Wei JC...Clinical practice recommendations for the use of imaging in the diagnosis and management of axial spondyloarthritis in Taiwan. International Journal of Rheumatic Diseases accepted 2019
8. KA Chu,.... JC Wei*. Association of Iron Deficiency Anemia with Tuberculosis in Taiwan: A Nationwide Population-Based Study. Plos one 2019 accepted
9. Li YJ, Perng WT, Tseng KY, Wang YH, Wei JC*.Association of gout medications and risk of Cataract: A population-based case-control study. QJM. 2019 Jul 9
10. Kuo-An Chu, Weishan Chen, Chung Y. Hsu, Yao-Min Hung*, and James Cheng-Chung Wei* Association of Scrub Typhus With the Risk of Autoimmune Diseases: A Population-Based Cohort Study. American Journal of Epidemiology 2019
11. Wang S, Wei JC, Huang JY, Perng WT, Zhang Z. The risk of herpes zoster among patients with ankylosing spondylitis: A population-based cohort study in Taiwan. Int J Rheum Dis. 2019 Jul 23

12. Yoshiya Tanaka1, Tsutomu Takeuchi2, Sakae Tanaka3, Atsushi Kawakami4, Manabu Iwasaki5, Yeong Wook Song6, Yi-Hsing Chen7, James Cheng-Chung Wei8, Sang-Heon Lee9, Mitsuhiro Rokuda10, Hiroyuki Izutsu10, Satoshi Ushijima10, Yuichiro Kaneko10, Rio Akazawa10, Teruaki Shiomi10, Emi Yamada10. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phaseIII trial (RAJ3) , ARD 2019 10.1136/annrheumdis-2019-215163
13. Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC * . Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. QJM. 2019 Jun 20
14. Yang DH, Leong PY, Sia SK, Wang YH, Wei JC * . Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus. J Clin Med. 2019 Jun 5
15. TSUNG-LIN TSAI, James Cheng-Chung Wei, Yue-Ting Wu, Yueh-Han Ku, Kun-Lin Lu, Yu-Hsun Wang and Jeng-Yuan Chiou. The Association Between Usage of Colchicine and Pneumonia: A Nationwide, Population-Based Cohort Study" . Frontiers in pharmacology
16. Chu KA, Chen W, Hung YM, Wei JC*. Increased risk of ankylosing spondylitis after Mycoplasma pneumonia: A Nationwide population-based study.Medicine (Baltimore). 2019 Jul
17. Che-Mai Chang,1 Yu-Wen Hsu,2 Henry Sung-Ching Wong,3 James Cheng-Chung Wei,4,5 Xiao Liu,6 Hsien-Tzung Liao,7,8,9,10 and Wei-Chiao Chang3,11,12,13 Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies. Disease Markers Volume 2019
18. Natalia V. Mikhailichellko, Viacheslav Kulagin, Takuma Shio, Jun Takanari, JC Wei. An open label trial of a standardized extract of cultured Lentinula edodes mycelia (ECLM) in children with refractory epilepsy. Functional Foods in Health and Disease. 2019

19. Tam LS, Wei JC*, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019 Feb 28
20. Chu KA, Chen W, Hsu CY, Hung YM, Wei JC*. Increased Risk of Rheumatoid Arthritis among Patients with Mycoplasma Pneumonia: A Nationwide Population-Based Cohort Study in Taiwan. PLoS One. 2019 Jan 14
21. A. Kavanaugh, H. Marzo-Ortega, R. Vender, C.-C. Wei, J. Birt, D.H. Adams, O. Benichou, C.-Y. Lin, P. Nash. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2018 Nov 19
22. Dafna Gladman, MD; Ana-Maria Orbai; Uta Klitz; James Cheng-Chung Wei; Gaia Gallo; Julie Birt; Suchitrita Rathmann; David Shrom; Helena Marzo-Ortega. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 29
23. Su-Boon Yong Jing-Yang Huang Jeng-Yuan Chiou James Cheng-Chung Wei* Adult outcome of juvenile idiopathic arthritis: A nationwide population-based retrospective cohort study in Taiwan. IJRD 27 February 2019
24. Yen FS, Chiang JH, Hwu CM, Yen YH, Lin BJ, Wei JC*, Hsu CC*.All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes. BMC Endocr Disord. 2019 Jan 5
25. Shi LH, Huang JY, Liu YZ, Chiou JY, Wu R, Wei JC*. Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study. Lupus. 2018 Dec
26. Yong SB, Su KW, Chen HH, Huang JY, Wu HJ, Wei JC*. Impact of chronic urticaria on systemic lupus erythematosus: A nationwide population-based study in Taiwan. J Dermatol. 2018 Oct 27

27. Yen FS, Chen W, Wei JC, Hsu CC, Hwu CM. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design. PLoS One. 2018 Oct 4
28. van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018 Oct 22
29. Xue YH, Peng YS, Ting HF, Peijer Hsieh J, Huang YK, Wang YH, Chiou JY, Wei JC*. Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study. Dement Geriatr Cogn Disord. 2018 Jun 28
30. CH Lo, JCC Wei, CF Tsai1, LC Li, SW Huang and CH Su. Syncope caused by complete heart block and ventricular arrhythmia as early manifestation of systemic lupus erythematosus in a pregnant patient: a case report. Lupus. 2018 Sep
31. Baeten D, Østergaard M, Wei JC*, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Jun 26
32. Huang-Hsi Chen*, Wuu-Tsun Perng, Jeng-Yuan Chiou, Yu-Hsun Wang, Jing-Yang Huang, James Cheng-Chung Wei. Risk of dementia among patients with Sjogren's syndrome: A nationwide population-based cohort study in Taiwan. Semin Arthritis Rheum. 2018 Jun 21

33. Yao-Min Hung§, Lichi Lin, Yu-Hsun Wang, James Cheng-Chung Wei§, Paul Yung-Pou Wang & Jeng-Yuan Chiou*. Combination Effect of Anti-Rheumatic Medications for Coronary Artery Diseases Risk in Rheumatoid Arthritis : A Nationwide Population-Based Cohort Study. Curr Med Res Opin. 2018 Jul 25
34. Su-Boon YONG, Huang-Hsi CHEN, Jing-Yang HUANG, James Cheng-Chung WEI*. Patients with urticaria are at a higher risk of anaphylaxis: A nationwide population-based retrospective cohort study in Taiwan. J Dermatol. 2018 Jul 13
35. Deng-Ho Yang, Jing-Yang Huang, Jeng-Yuan Chiou, James Cheng-Chung Wei*. Analysis of socioeconomic status in the patients with rheumatoid arthritis. Int J Environ Res Public Health. 2018 Jun 7
36. Uta Kiltz, Désirée van der Heijde, Annelies Boonen, Nurullah Akkoc, Wilson Bautista-Molano, Ruben Burgos-Vargas, James Cheng-Chung Wei, Praveena Chiowchanwisawakit, Maxime Dougados, M Tuncay Duruoz, Bassel Kamal Elzorkany, Inna Gaydukova, Lianne S Gensler, Michele Gilio, Simeon Grazio, Jieruo Gu, Robert D Inman, Tae-Jong Kim, Victoria Navarro-Compan, Helena Marzo-Ortega, Salih Ozgocmen,21Fernando Pimentel dos Santos, Michael Schirmer, Simon Stebbings, Filip E Van den Bosch, Astrid van Tubergen, Juergen Braun. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018 Sep
37. Sun MH, Liao YJ, Lin CC, Chiang RP, Wei JC*. Association between obstructive sleep apnea and optic neuropathy: a Taiwanese population-based cohort study. Eye (Lond). 2018 Apr 26
38. Hung YM, Wang YH, Lin L, Wang PYP, Chiou JY, Wei JC*. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. Int J Clin Pract. 2018 Apr 24

39. Wu XF, Huang JY, Chiou JY, Chen HH, Wei JC*, Dong LL. Increased risk of coronary heart disease among patients with primary Sjögren's syndrome: a nationwide population-based cohort study. Sci Rep. 2018 Feb 2
40. F-S. Yen, J-H. Chiang, C-W. Pan, B.J. Lin, J. Cheng-Chung Wei*, C-C. Hsu*, Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. Diabetes Res Clin Pract. 2018 Apr 12
41. Tam HW, Chen CM, Leong PY, Chen CH, Li YC, Wang YH, Lin LC, Chiou JY, Wei JC*. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. Int J Rheum Dis. 2018 Jan 25
42. Wei JC, Shi LH, Huang JY, Wu XF, Wu R, Chiou JY. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study. J Rheumatol. 2018 Jan 15
43. Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, Kuo MC, Lam HC, Lee IT, Liang TH, Lin HY, Lin SC, Tsai WP, Tsay GJ, Wei JC, Yang CH, Tsai WC. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018 Jan 24
44. Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu J, Wei JCC, Dougados M; ASAS-FLARE study group. An Assessment in SpondyloArthritis International Society(ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018 Jan
45. Chen CM, Shen PS, Wei JC, Lin L. A semiparametric mixture cure survival model for left-truncated and right-censored data. Biom J. 2017 Mar;59(2):270-290. doi: 10.1002/bimj.201500267. Epub 2016 Nov 23

46. Chen KT, Chen YC, Fan YH, Lin WX, Lin WC, Wang YH, Lin L, Chiou JY, Wei JC*. Rheumatic diseases are associated with a higher risk of dementia: A nation-wide, population-based, case-control study. Int J Rheum Dis. 2017 Dec 15
47. Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu J, Wei JCC, Dougados M; ASAS-FLARE study group.An Assessment in SpondyloArthritis international Society(ASAS)-endorsed definition of clinically important worsening in axial Spondyloarthritis based on the ASDAS. Ann Rheum Dis. 2018 Jan
48. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators.Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29
49. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response totumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 Jun 10
50. Weng KP, Wei JC*, Hung YM, Huang SH, Chien KJ, Lin CC, Huang SM, Lin CL, Cheng MF. Enterovirus Infection and Subsequent Risk of Kawasaki Disease: A Population-Based Cohort Study. Pediatr Infect Dis J. 2017 Aug 19
51. Wu MC, Xu X, Chen SM, Tyan YS, Chiou JY, Wang YH, Lin LC, Chen CM, Wei JC*. Impact of Sjogren's syndrome on Parkinson's disease: a nationwide case-control study. PLoS One. 2017 Jul 13

52. Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis Rheumatol. 2016 Dec
53. Hung YM, Lin L, Chen CM, Chiou JY, Wang YH, Wang PY, Wei JC*. The Effect of Anti-Rheumatic Medications for Coronary Artery Diseases Risk in Patients with Rheumatoid Arthritis Might be Changed Over Time: A Nationwide Population-Based Cohort Study. PLoS One. 2017 Jun 28
54. Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B. Efficacy and Safety of Secukinumab in Asian Patients with Active Ankylosing Spondylitis: 52-Week Pooled Results from Two Phase 3 Studies. Int J Rheum Dis. 2017 May 25
55. X. Baraliakos, A. Kivitz, A. Deodhar, J. Braun, J. Wei, E. Delicha, Z. Talloczy, B. Porter. Long-term effects of interleukin 17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2017 May 15
56. Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Jan 27
57. CHIEN-YING LEE, CHENG-CHUNG WEI, MIN-CHIEN YU, CHING-CHE LIN, SHUENN-JYI SHEU, JEN-HUNG YANG, CHIEN-YING CHIANG, KUANG-HUA HUANG and YU-HSIANG KUAN. Hair growth effect of traditional Chinese medicine BeauTop on androgenetic alopecia patients: A randomized double-blind placebo-controlled clinical trial. Exp Ther Med. 2017 Jan

58. Hsi-Kai Tsou, MD/PhD, Ting-Hsien Kao, MD, PhD, Peir-An Tsai, PhD, Hsien-Te Chen, MD/ PhD, Hung-Chuan Pan MD/PhD, James Cheng-Chung Wei, MD/PhD*. Serum Beta-endorphin Changes in Lumbar Facet Syndrome Treated with Radiofrequency Lumbar Facet Denervation – A Randomized Controlled Study. Journal of Spine. 2016
59. Wei-Chiao Chen, James Cheng-Chung Wei*, Hsing-Fang Lu, Peng Yeong Woon, Yu-Wen Hsu, Jin-ding Huang, Wei-Chiao Chang. rs657075 (CSF2) Is Associated with the Disease Phenotype (BAS-G) of Ankylosing Spondylitis. Int. J. Mol. Sci. 2017 Jan 3
60. Hong-Wei TAM, Kai-Jieh YEO, Pui-Ying LEONG, Chao-Hsi CHEN, Yuan-Chao LI, Chien-Ming MA, Yu-Hsun WANG, Jeng-Yuan CHIOU and James Cheng-Chung Wei*. Sulfasalazine Might Reduce Risk of Cardiovascular Diseases in Patients with Ankylosing Spondylitis. A Nationwide Population-Based Retrospective Cohort Study. Int J Rheum Dis. 2016 Dec 10
61. James Cheng-Chung WEI, Wen-Chan TSAI, Gustavo CITERA, Sameer KOTAK and Lyndon LLAMADO. Efficacy and safety of etanercept in patients from Latin America, Central Europe, and Asia with early non-radiographic axial spondyloarthritis. Int J Rheum Dis. 2016 Nov 11
62. Chang WP, Kuo CN, Kuo LN, Wang YT, Perng WT, Kuo HC, Wei JC. Increase risk of allergic diseases in patients with ankylosing spondylitis: A 10-year follow-up population-based study in Taiwan. Medicine. 2016 Nov
63. CHIEN-YING LEE, MIN-CHIEN YU, WUU-TSUN PERNG, CHUN-CHE LIN, MING-YUNG LEE, JAMES CHENG-CHUNG WEI* AND HUNG-CHE SHIH. No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus Casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial. Chin J Integr Med. 2017 Aug

64. Wen-Jen Cheng, Yu-Ling Wei, James Cheng-Chung Wei, Chia-Wei Lin, Hui-Yin Lu, Yu-Pu Hsia, Pei-Jane Tsai, YingChun Lai, Yu-Liang Kuo and Ming-Shiou Jan. Effects of Klebsiella pneumonia on Toll-Like Receptor-Dependent Endoplasmic Reticulum Stress-Related Signaling Pathways and Gene Expression and Promotes HLA-B27 Misfolding. Journal of Pharmacy and Pharmacology 4 (2016)
65. Chyong-Mei Chen, Pao-sheng Shen*, James Cheng-Chung Wei, Lichi Lin. A Semiparametric Mixture Cure Survival Model for Left truncated and Right-Censored Data. Biom J. 2017 Mar
66. Wu LC, Leong PY, Yeo KJ, Li TY, Wang YH, Chiou JY*, Wei JC*. Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine. 2016 Sep
67. G. Thomas, D. Willner, P. Robinson, A. Cortes, R. Duan, M. Rudwaleit, N. Akkoc, J. Braun, C. Chou, W. Maksymowych, S. Ozgocmen, E. Roussou, J. Sieper, R. Valle-Onate, D. van der Heijde, J. Wei. Genetic diagnostic profiling in axial spondyloarthritis: a real world study. Clin Exp Rheumatol. 2017 Mar-Apr
68. Ruben Burgos-Varga; James Cheng-Chung Wei*; Mahboob Rahman; Nurullah Akkoc; Syed Atiqul Haq; Mohammed Hammoudeh; Ehab Mahgoub; Ena Singh; Lyndon John Llamado; Khalid Shirazy; Sameer Kotak; Constance Hammond; Ron Pedersen; Qi Shen; Bonnie Vlahos. The prevalence and clinical characteristics of non-radiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multi-national and multi-centered study. Arthritis Research & Therapy. 2016 Jun 7
69. Marsman AF, Kneepkens EL, Ruwaard J, Wei JC, Nurmohamed MT, van Denderen C, van der Horst-Bruinsma IE, Rispens T, Wolbink G. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. Scand. J Rheumatol. 2016 Jul

70. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24
71. Ko TM, Tsai CY, Chen SY, Chen KS, ..., Chen YT, Shen CY; Taiwan Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015 Sep 23
72. Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct
73. Tong-ling Yuan, Jin Chen, Yan-li Tong, Yan Zhang, Yuan-Yuan Liu, James Cheng-Chung Wei, Yi Liu, Yi Zhao and Martin M. Herrmann. Serum Heme Oxygenase-1 and BMP-7 are potential Biomarkers for Bone Metabolism in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Biomed Res Int. 2016
74. Wei CY, Kung WM, Chou YS, Wang YC, Tai HC, Wei JC*. Cardiac Autonomic Function in Patients with Ankylosing Spondylitis: A Case-Control Study. Medicine. 2016 May
75. Yao-Min Hung, Wei-Pin Chang, James Cheng-Chung Wei * , Pesus Chou, Paul Yung-Pou Wang. Midlife Ankylosing spondylitis increases the risk of cardiovascular diseases in males 5 years later: a national population-based study. Medicine. 2016 May

76. Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M, on behalf of ASAS. Predictive validity of theASAS-Classification Criteria for Axial and Peripheral Spondyloarthritis after follow-up in the ASAS-cohort: A final analysis. Ann Rheum Dis. 2016 Jun
77. James Cheng-Chung Wei, M.D., Ph. D.; Hsiu-Chen Huang, Ph. D.; Wei-Jen Chen,Ph. D.; Chien-Ning Huang, M.D., Ph. D.; Chiung-Huei Peng, Ph. D.; Chih-Li Lin, Ph. D. Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia. Eur J Pharmacol. 2016 Jan 5
78. Chi Chiu Mok, Wen Chan Tsai, Der Yuan Chen and James Cheng Chung Wei*. Immunogenicity of anti-TNF biological agents in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016
79. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J, Togo O, Mashimo H.Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016
80. Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, Huang CM, Wang CR, Weng CT, Yu CL, Hsieh SC, Tsai JC, Lai WT, Tsai WC, Yin GD, Ou TT, Cheng KH, Yen JH, Liou TL, Lin TH, Chen DY, Hsiao PJ, Weng MY, Chen YM, Chen CH, Liu MF, Yen HW, Lee JJ, Kuo MC, Wu CC, Hung SY, Luo SF, Yang YH, Chuang HP, Chou YC, Liao HT, Wang CW, Huang CL, Chang CS, Lee MT, Chen P, Wong CS, Chen CH, Wu JY, Chen YT, Shen CY; Taiwan Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015 Sep 23

81. James Cheng-Chung Wei*, Henry Sung-Ching Wong*, Yu-Wen Hsu, Ya-Feng Wen, Wen-Chang Wang, Ruey-Hong Wong, Hsing-Fang Lu, Floris A. van Gaalen, Wei-Chiao Chang. Interaction between HLA-B60 and HLA-B27 as a better predictor of ankylosing spondylitis in a Taiwanese population. PLoS One. 2015 Oct 15
82. Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct
83. James Cheng-Chung Wei. Editorial: Spine and Rheumatic Diseases. Biomed Res Int. 2015
84. Ming-Lung Chuang, Tzu-Chin Wu, Yau-Tung Wang, Yau-Chen Wang, Thomas C-Y Tsao, James Cheng-Chung Wei*, Chia-Yin Chen, I-Feng Lin Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--a Randomized Placebo Controlled Double Blind Clinical Trial. PLoS One, 2015 Jun;10
85. Cheng-Yu Wei, Chia-Cheng Sun, James Cheng-Chung Wei, Hsu-Chih Tai, Chien-An Sun, Chian-Fang Chung, Yu-Ching Chou, Pi-Li Lin and Tsan Yang. Association between Hyperuricemia and Metabolic Syndrome: An Epidemiological Study of a Labor Force Population in Taiwan. Biomed Res Int. 2015
86. Ya-Feng Wen, James Cheng-Chung Wei, Yu-Wen Hsu, Hung-Yi Chiou,Henry Sung-Ching Wong, Ruey-Hong Wong, Shiro Ikegawa, Wei-Chiao Chang*. rs10865331 Associated with Susceptibility and Disease Severity of Ankylosing Spondylitis in a Taiwanese Population. PLoS One. 2014 Sep

87. Lin-Fen Hsieh, Chih-Cheng Chuang*, Ching-Shiang Tseng, James Cheng-Chung Wei*, Wei-Chun Hsu, and Yi-Jia Lin. Combined Home Exercise Is More Effective Than Range-of-Motion Home Exercise in Patients with Ankylosing Spondylitis: A Randomized Controlled Trial. Biomed Res Int. 2014 Sep
88. JC Wei. Author’s Reply to Wendling and Prati: ‘‘Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs’’. Drugs. 2014 Sep
89. Yang DH*, Tu CC, Wang SC, Wei CC*, Cheng YW*. Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. Rheumatology International. 2014 July
90. James Cheng-Chung Wei. Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs. Drugs. 2014 Jul